MARATTO

article · Frontiers in Molecular Biosciences

The ameliorative effect of chrysin on ovarian toxicity caused by methidathion in female rats

20241 citationOpen accessMinia University

Abstract

<b>Introduction:</b> Methidathion (MD) is commonly used in agriculture and has adverse effects on reproduction. Chrysin (CHR) has several advantageous properties, such as anti-inflammatory, anti-cancer, and antioxidant properties. The purpose of the current investigation was to assess CHR's therapeutic efficacy in reducing ovarian toxicity brought on by MD. <b>Methods:</b> Twenty-four female rats were divided into four groups of six animals each. Group 1 served as a control, while group 2 rats received MD (5 mg/kg). Rats in Group 3 received CHR at a dose of 50 mg/kg. Rats in group 4 received treatment with CHR after MD intoxication. <b>Results and Discussion:</b> Our research revealed that MD significantly (<i>p</i> < 0.001) increased the levels of MDA, caspase-3, FSH, LH, CA-125, and TNF-α but significantly (<i>p</i> < 0.001) decreased the levels of SOD, GSH, E2, and progesterone when compared to the control and CHR groups. After receiving CHR therapy, damage induced by MD was significantly (<i>p</i> < 0.001) repaired. <b>Conclusion:</b> This study showed that CHR could mitigate the adverse effects that MD causes to the ovaries by decreasing oxidative stress, inflammation, and apoptosis; improving antioxidant status; and restoring the correct ratio of sex hormones.

Research topics

  • Bee Products Chemical Analysis
  • Saffron Plant Research Studies
  • Natural Antidiabetic Agents Studies

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.3389/fmolb.2024.1470711

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.